Find stocks with consensus strong buy ratings，and price under target price

Below is an interactive table containing all U.S-listed stocks that • Carry a consensus analyst recommendation of “Strong Buy”, and • Are currently trading below their Street 12-month target price. Click any column header to sort, or export the full list for deeper analysis. ```jgy-json { "show_type": "jgyNewLowcode", "config": { "type": "iwcapp/aimeScreenerTable", "version": "0.0.1", "url": "//cdn.ainvest.com/frontResources/s/foiegras/aimeScreenerTable/0.0.1/aimeScreenerTable@0.0.1index.js", "query_type": "stock" }, "data": { "type": "remote-url", "url": "https://cdn.ainvest.com/backtest/agent/session/quant/tangmoming/ai_screener/cb39a94a-e134-487b-b744-5e2a3ccb93b5.json" } } ``` Quick takeaways from the screen (sample highlights): • Wells Fargo (WFC) – Still rated “Strong Buy” by the Street, with ~18 % upside implied by the average target price; investors see continued tailwinds from higher net-interest margins. • Klaviyo (KVYO) – Newly public mar-tech platform already sporting unanimous bullish calls, yet trades roughly 22 % below its median target; worth watching as lock-up expirations approach. • Wynn Resorts (WYNN) – Analysts remain bullish on Macau recovery; the shares sit about 15 % under consensus value. • Smaller-cap biotech names such as Atossa Therapeutics (ATOS) and Humacyte (HUMA) also make the cut, reflecting high conviction from covering analysts despite recent volatility. Feel free to explore the table for further details like exact upside percentages, sector breakdowns, and coverage depth.